These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31112398)

  • 21. Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.
    Petit C; Blanchard P; Pignon JP; Lueza B
    Syst Rev; 2019 Apr; 8(1):96. PubMed ID: 30987679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
    Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
    Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update in pediatric nasopharyngeal undifferentiated carcinoma.
    Claude L; Jouglar E; Duverge L; Orbach D
    Br J Radiol; 2019 Oct; 92(1102):20190107. PubMed ID: 31322911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.
    Lee AW; Ngan RK; Tung SY; Cheng A; Kwong DL; Lu TX; Chan AT; Chan LL; Yiu H; Ng WT; Wong F; Yuen KT; Yau S; Cheung FY; Chan OS; Choi H; Chappell R
    Cancer; 2015 Apr; 121(8):1328-38. PubMed ID: 25529384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma.
    Limkin EJ; Blanchard P
    Br J Radiol; 2019 Oct; 92(1102):20190068. PubMed ID: 31150279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
    Lee AWM; Tung SY; Ng WT; Lee V; Ngan RKC; Choi HCW; Chan LLK; Siu LL; Ng AWY; Leung TW; Yiu HHY; O'Sullivan B; Chappell R
    Cancer; 2017 Nov; 123(21):4147-4157. PubMed ID: 28662313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
    Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
    Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.
    Lee AW; Tung SY; Ngan RK; Chappell R; Chua DT; Lu TX; Siu L; Tan T; Chan LK; Ng WT; Leung TW; Fu YT; Au GK; Zhao C; O'Sullivan B; Tan EH; Lau WH
    Eur J Cancer; 2011 Mar; 47(5):656-66. PubMed ID: 21112774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials.
    Liang ZG; Zhu XD; Zhou ZR; Qu S; Du YQ; Jiang YM
    Asian Pac J Cancer Prev; 2012; 13(11):5747-52. PubMed ID: 23317250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J
    Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: meta-analysis of 1,096 patients from 11 randomized controlled trials.
    Liang ZG; Zhu XD; Tan AH; Jiang YM; Qu S; Su F; Xu GZ
    Asian Pac J Cancer Prev; 2013; 14(1):515-21. PubMed ID: 23534786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes.
    Xu T; Zhu G; He X; Ying H; Hu C
    Oral Oncol; 2014 Feb; 50(2):71-6. PubMed ID: 24315404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials.
    Chen YP; Tang LL; Yang Q; Poh SS; Hui EP; Chan ATC; Ong WS; Tan T; Wee J; Li WF; Chen L; Ma BBY; Tong M; Tan SH; Cheah SL; Fong KW; Sommat K; Soong YL; Guo Y; Lin AH; Sun Y; Hong MH; Cao SM; Chen MY; Ma J
    Clin Cancer Res; 2018 Apr; 24(8):1824-1833. PubMed ID: 29431618
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.